Janssen v. Pharmascience

We successfully represented Janssen in defending the validity of the patent relating to Janssen’s INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product used to treat schizophrenia.

In seeking to get approval for its generic paliperidone palmitate product, Pharmascience alleged that the claims of Janssen’s patent were invalid on the basis of obviousness and improper subject-matter (method of medical treatment). The Federal Court agreed with Janssen and upheld the validity of the claims, finding that the claims are inventive and cover patentable subject-matter.